## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat
Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Scribed by John D. Hainsworth; Joan B. Erland; John H. Barton; Dana S. Thompson; M. Patrick Stagg; James E. Bradof; Thomas W. Twele; F. Anthony Greco
- Book ID
- 115076538
- Publisher
- CIG Media Group, LP.
- Year
- 2003
- Tongue
- English
- Weight
- 120 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1525-7304
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND The goal of the current study was to evaluate the feasibility, toxicity, and efficacy of a novel combination of weekly docetaxel and gemcitabine for elderly patients and patients with poor performance status who had advanced‐stage small cell lung carcinoma (SCLC). ## MET
## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme